These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 33336433)

  • 1. Serum markers of pulmonary epithelial damage in systemic sclerosis-associated interstitial lung disease and disease progression.
    Stock CJW; Hoyles RK; Daccord C; Kokosi M; Visca D; De Lauretis A; Alfieri V; Kouranos V; Margaritopoulos G; George PM; Molyneaux PL; Chua F; Maher TM; Abraham DJ; Ong V; Donovan J; Sestini P; Denton CP; Wells AU; Renzoni EA
    Respirology; 2021 May; 26(5):461-468. PubMed ID: 33336433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
    Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
    Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KL6 and IL-18 levels are negatively correlated with respiratory function tests and ILD extent assessed on HRCT in patients with systemic sclerosis-related interstitial lung disease (SSc-ILD).
    Sieiro Santos C; Antolín SC; Lorenzo JC; Garay CL; Morales CM; de Miguel EB; Guerrero MR; Herránz LS; Álvarez ED
    Semin Arthritis Rheum; 2024 Apr; 65():152366. PubMed ID: 38290372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetic changes in serum KL-6 levels predict disease progression in patients with systemic sclerosis-associated interstitial lung disease.
    Watanabe S; Kase K; Saeki K; Ohkura N; Murata A; Waseda Y; Takato H; Ichikawa Y; Yasui M; Kasahara K
    Respir Med; 2022 Jan; 191():106689. PubMed ID: 34844174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of Candidate Serum Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease.
    Elhai M; Hoffmann-Vold AM; Avouac J; Pezet S; Cauvet A; Leblond A; Fretheim H; Garen T; Kuwana M; Molberg Ø; Allanore Y
    Arthritis Rheumatol; 2019 Jun; 71(6):972-982. PubMed ID: 30624031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated Serum Krebs von den Lungen-6 in Early Disease Predicts Subsequent Deterioration of Pulmonary Function in Patients with Systemic Sclerosis and Interstitial Lung Disease.
    Kuwana M; Shirai Y; Takeuchi T
    J Rheumatol; 2016 Oct; 43(10):1825-1831. PubMed ID: 27481907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18.
    Volkmann ER; Tashkin DP; Kuwana M; Li N; Roth MD; Charles J; Hant FN; Bogatkevich GS; Akter T; Kim G; Goldin J; Khanna D; Clements PJ; Furst DE; Elashoff RM; Silver RM; Assassi S
    Arthritis Rheumatol; 2019 Dec; 71(12):2059-2067. PubMed ID: 31233287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KL-6 But Not CCL-18 Is a Predictor of Early Progression in Systemic Sclerosis-related Interstitial Lung Disease.
    Salazar GA; Kuwana M; Wu M; Estrada-Y-Martin RM; Ying J; Charles J; Mayes MD; Assassi S
    J Rheumatol; 2018 Aug; 45(8):1153-1158. PubMed ID: 29961690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum levels of Krebs von den Lungen-6 as a promising marker for predicting occurrence and deterioration of systemic sclerosis-associated interstitial lung disease from a Chinese cohort.
    Cao XY; Hu SS; Xu D; Li MT; Wang Q; Hou Y; Zeng XF
    Int J Rheum Dis; 2019 Jan; 22(1):108-115. PubMed ID: 30592376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seasonal fluctuation of serum Krebs von den Lungen-6 levels in systemic sclerosis-associated interstitial lung disease.
    Hirose H; Higuchi T; Takagi K; Tochimoto A; Ichimura Y; Harigai M; Kawaguchi Y
    Int J Rheum Dis; 2024 Jul; 27(7):e15254. PubMed ID: 38973340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease progression and changes in KL-6 in patients with limited cutaneous systemic sclerosis-associated interstitial lung disease.
    Takei R; Yamano Y; Kataoka K; Fukihara J; Sasano H; Yokoyama T; Matsuda T; Kimura T; Kondoh Y
    Respir Investig; 2024 Jan; 62(1):44-48. PubMed ID: 37944381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic role of KL-6 in SSc-ILD patients with pleuroparenchymal fibroelastosis.
    d'Alessandro M; Bellisai F; Bergantini L; Cameli P; D'Alessandro R; Mazzei MA; Gentili F; Conticini E; Selvi E; Frediani B; Matucci-Cerinic M; Bargagli E
    Eur J Clin Invest; 2021 Aug; 51(8):e13543. PubMed ID: 33759179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulatory Serum Krebs von Den Lungen-6 and Surfactant Protein-D Concentrations Predict Interstitial Lung Disease Progression and Mortality.
    Rai M; Parthasarathi A; Beeraka NM; Kaleem Ullah M; Malamardi S; Padukudru S; Siddaiah JB; Uthaiah CA; Vishwanath P; Chaya SK; Ramaswamy S; Upadhyay S; Ganguly K; Mahesh PA
    Cells; 2023 Apr; 12(9):. PubMed ID: 37174681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases.
    Ishikawa N; Hattori N; Yokoyama A; Kohno N
    Respir Investig; 2012 Mar; 50(1):3-13. PubMed ID: 22554854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Krebs von den Lungen-6 as biomarker of the new progressive fibrotic phenotype of interstitial lung disease.
    d'Alessandro M; Conticini E; Bergantini L; Mazzei MA; Bellisai F; Selvi E; Cameli P; Frediani B; Bargagli E
    Tissue Cell; 2024 Oct; 90():102516. PubMed ID: 39137538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic Value of Krebs von den Lungen (KL-6) for Interstitial Lung Disease: A European Prospective Cohort.
    Millan-Billi P; Castellví I; Martinez-Martinez L; Mariscal A; Barril S; D'Alessandro M; Franquet T; Castillo D
    Arch Bronconeumol; 2024 Jun; 60(6):350-355. PubMed ID: 38644152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum KL-6 levels reflect the severity of interstitial lung disease associated with connective tissue disease.
    Lee JS; Lee EY; Ha YJ; Kang EH; Lee YJ; Song YW
    Arthritis Res Ther; 2019 Feb; 21(1):58. PubMed ID: 30764869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis.
    De Lauretis A; Sestini P; Pantelidis P; Hoyles R; Hansell DM; Goh NS; Zappala CJ; Visca D; Maher TM; Denton CP; Ong VH; Abraham DJ; Kelleher P; Hector L; Wells AU; Renzoni EA
    J Rheumatol; 2013 Apr; 40(4):435-46. PubMed ID: 23378460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum KL-6 and surfactant protein-D as monitoring and predictive markers of interstitial lung disease in patients with systemic sclerosis and mixed connective tissue disease.
    Yamakawa H; Hagiwara E; Kitamura H; Yamanaka Y; Ikeda S; Sekine A; Baba T; Okudela K; Iwasawa T; Takemura T; Kuwano K; Ogura T
    J Thorac Dis; 2017 Feb; 9(2):362-371. PubMed ID: 28275485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Relevance of the Serial Measurement of Krebs von den Lungen-6 Levels in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease.
    Shirai Y; Fukue R; Kaneko Y; Kuwana M
    Diagnostics (Basel); 2021 Oct; 11(11):. PubMed ID: 34829353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.